Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

Autor: Oliveira, M., Falato, C., Cejalvo, J.M., Vila, M. Margelí, Tolosa, P., Salvador-Bofill, F.J., Cruz, J., Arumi, M., Luna, A.M., Guerra, J.A., Vidal, M., Martínez-Sáez, O., Paré, L., González-Farré, B., Sanfeliu, E., Ciruelos, E., Espinosa-Bravo, M., Pernas, S., Izarzugaza, Y., Esker, S., Fan, P.-D., Parul, P., Santhanagopal, A., Sellami, D., Villacampa, G., Ferrero-Cafiero, J.M., Pascual, T., Prat, A.
Zdroj: In Annals of Oncology August 2023 34(8):670-680
Databáze: ScienceDirect